Dexmedetomidine is under clinical development by Teikoku Pharma USA and currently in Phase II for Post-Operative Pain. According to GlobalData, Phase II drugs for Post-Operative Pain have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dexmedetomidine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexmedetomidine overview
Dexmedetomidine (TPU-006) is under development for the treatment of chronic pain and post-operative pain in hallux valgus (Bunion). The drug candidate is formulated as a 3 days patch and administered through transdermal route. It acts by targeting selective alpha 2 adrenergic receptors. The drug candidate is developed based on Matrix patch technology.
Teikoku Pharma USA overview
Teikoku Pharma USA (Teikoku Pharma), a subsidiary of Teikoku Seiyaku Co Ltd, s a specialty pharmaceutical company that develops and manufactures pharmaceutical products based on its delivery platform technologies in the therapeutic areas of CNS, pain management and oncology. The company offers products such as lidoderm, a prescription, topical, hydrogel patch for post-herpetic neuralgia (PHN) and also provides analgesia directly to the affected nerves. Teikoku Pharma’s versatis is used for the management of neuropathic pain associated with previous herpes zoster infection. The company also offers non-alcohol docetaxel injections used for the treatment of non-small cell lung cancer, breast cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer. Its pipeline products include rasagiline patch (TPU-002) for parkinson’s disease, TPU-010 indicated for puritis and a dexmedetomidine patch (TPU-006) for pain management. Teikoku Pharma is headquartered in San Jose, California, the US.
For a complete picture of Dexmedetomidine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
